Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on February 10, 2005

Arteriosclerosis, Thrombosis, and Vascular Biology. 2005
Published online before print February 10, 2005, doi: 10.1161/01.ATV.0000158996.03867.72
A more recent version of this article appeared on June 1, 2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/6/1128    most recent
01.ATV.0000158996.03867.72v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoenig, M. R.
Right arrow Articles by Campbell, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoenig, M. R.
Right arrow Articles by Campbell, J. H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Peripheral Arterial Disease

Submitted on November 29, 2004
Accepted on January 28, 2005

Tissue-Engineered Blood Vessels. Alternative to Autologous Grafts?

Michel R. Hoenig ; Gordon R. Campbell ; Barbara E. Rolfe ; and Julie H. Campbell *

From the Centre for Research in Vascular Biology, School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia.

* To whom correspondence should be addressed. E-mail: julie.campbell{at}uq.edu.au.

Abstract--Although vascular bypass grafting remains the mainstay for revascularization for ischemic heart disease and peripheral vascular disease, many patients do not have healthy vessels suitable for harvest. Thus, prosthetic grafts made of synthetic polymers were developed, but their use is limited to high-flow/low-resistance conditions because of poor elasticity, low compliance, and thrombogenicity of their synthetic surfaces. To fill this need, several laboratories have produced in vivo or in vitro tissue-engineered blood vessels using molds or prosthetic or biodegradable scaffolds, but each artificial graft has significant problems. Recently, conduits have been grown in the peritoneal cavity of the same animals in which they will be grafted, ensuring no rejection, in the short time of 2 to 3 weeks. Remodeling occurs after grafting such that the tissue is almost indistinguishable from native vessels. This conduit is derived from cells of bone marrow origin, opening new possibilities in vascular modeling and remodeling.


Key words: artificial arteries • bypass grafts • myofibroblasts • tissue engineering • tissue scaffolds




This article has been cited by other articles:


Home page
Card Surg AdultHome page
R. F. Padera Jr. and F. J. Schoen
Pathology of Cardiac Surgery
Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178.
[Full Text]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Lahtinen, P. Blomberg, G. Baliulis, F. Carlsson, H. Khamis, and V. Zemgulis
In vivo h-VEGF165 gene transfer improves early endothelialisation and patency in synthetic vascular grafts
Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 383 - 390.
[Abstract] [Full Text] [PDF]